Skip to main content

Table 2 Prevalence of diagnoses

From: The diagnostic yield of the first episode of a periodic health evaluation: a descriptive epidemiology study

Categories

Prevalence, n (%)

N = 491

No. Not Patient Prompted

USPSTF

Recommendationsfor Screening

ENDOCRINE

Adrenal adenoma

2 (0.4)

2

NR

Diabetes mellitus Type 2

3 (0.6)

3

B*

Dyslipidemia

40 (8.2)

40

A**

Chronic fatigue

1 (0.2)

1

NR

Hyperparathyroidism

6 (1.2)

6

NR

Hyperthyroidism

2 (0.4)

2

I

Elevated lipoprotein (a)

12 (2.4)

12

NR

Metabolic syndrome

6 (1.2)

6

NR

   Obesity

95 (19.4)

88

B

   Class I

72

67

 

   Class II

13

12

 

   Class III

10

9

 

Osteoporosis

9 (1.8)

8

B

Thyroid nodule

4 (0.8)

2

I

Hashimoto’s thyroiditis

1 (0.2)

1

I

Thyrotoxicosis

1 (0.2)

1

I

Vertebral compression fracture

2 (0.4)

2

NR

TOTAL

184 (37.4)

174

 

MALIGNANCY

Non-melanoma skin

8 (1.6)

8

I

Melanoma

7 (1.4)

4

I

Prostate cancer

4 (0.8)

4

D

Renal cell carcinoma

1 (0.2)

1

NR

Pancreatic cancer

1 (0.2)

0

D

TOTAL

21 (4.2)

17

 

PRE-MALIGNANT

Colon polyp (large, multiple, tubulovillous+)

5 (1.0)

5

A

PSA elevation

6 (1.2)

6

D

Night sweats

2 (0.4)

0

NR

TOTAL

13 (2.6)

11

 

CARDIOVASCULAR

Aortic aneurysm, thoracic

1 (0.2)

1

NR

Aortic aneurysm, abdominal

1 (0.2)

1

B

Aortic dilatation (any area)

2 (0.4)

2

NR

Moderate aortic stenosis

1 (0.2)

1

NR

Aortic valve regurgitation

2 (0.4)

2

NR

Bicuspid aortic valve

1 (0.2)

1

NR

CAD, stable

3 (0.6)

3

D

CAD, unstable

1 (0.2)

0

NR

Chest pain

4 (0.8)

3

NR

LVH

2 (0.4)

2

NR

Patent foramen ovale

1 (0.2)

1

NR

Abnormal stress test

2 (0.4)

2

D, I***

Congestive heart failure

1 (0.2)

0

NR

Peripheral artery disease

1 (0.2)

0

D

TOTAL

23 (4.6)

19

 

GASTROENTEROLOGY

Barrett’s esophagus

1 (0.2)

1

NR

Crohn’s disease

1 (0.2)

1

NR

Diverticulitis

4 (0.8)

3

NR

Diverticulosis

1 (0.2)

1

NR

Esophagitis

6 (1.2)

5

NR

Helicobacter pylori

4 (0.8)

3

NR

Hemochromatosis

1 (0.2)

1

D

Hepatitis C

1 (0.2)

1

D

Splenomegaly

2 (0.4)

2

NR

Steatohepatitis

8 (1.6)

8

NR

Mesenteric abscess

1 (0.2)

0

NR

Hematochezia

2 (0.4)

0

NR

TOTAL

32 (6.4)

25

 

NEUROLOGY

Cerebral infarction

1 (0.2)

0

NR

Lumbar stenosis

1 (0.2)

1

NR

Neuropathy

6 (1.2)

2

NR

Paresthesia

12 (2.4)

4

NR

Pituitary adenoma

1 (0.2)

1

NR

Seizure

1 (0.2)

1

NR

Syringomyelia

1 (0.2)

1

NR

Spinal syrinx

1 (0.2)

1

NR

Gliomatosis cerebri

1 (0.2)

0

NR

Transient ischemic attack

1 (0.2)

0

NR

TOTAL

26 (5.2)

11

 

PULMONARY

COPD

3 (0.6)

3

D

Obstructive sleep apnea

24 (4.9)

11

NR

Pleural effusion

1 (0.2)

1

I

Pleural thickening

1 (0.2)

1

I

Pneumonitis

2 (0.4)

2

NR

Upper airway resistance

1 (0.2)

1

NR

Asthma

1 (0.2)

0

NR

LTBI

1 (0.2)

1

NR

TOTAL

34 (6.9)

20

 

NEPHROLOGY

IGA nephropathy

1 (0.2)

1

NR

Medullary sponge kidney

1 (0.2)

1

NR

Nephrolithiasis

3 (0.6)

2

NR

Polycystic kidney disease

2 (0.4)

2

NR

Prerenal azotemia

1 (0.2)

1

NR

Renal insufficiency

3 (0.6)

3

NR

TOTAL

11 (2.2)

10

 

OPHTHALMOLOGY

Macular degeneration

3 (0.6)

3

NR

Glaucoma

4 (0.8)

4

I

Diabetic retinopathy

1 (0.2)

1

NR

TOTAL

8 (1.6)

8

 

PSYCHIATRIC

Depression

9 (1.8)

1

B

Eating disorder

1 (0.2)

1

NR

Adjustment disorder

2 (0.4)

0

NR

Anxiety

8 (1.6)

1

NR

TOTAL

20 (4.0)

3

 

HEALTH HABITS

Alcohol abuse

5 (1.0)

1

B

Nicotine dependency

43 (8.8)

2

A

TOTAL

48 (9.8)

3

 

OTHER

Hearing loss (severe/asymmetric)

5 (1.0)

3

NR

Seronegative spondyloarthropathy

1 (0.2)

0

NR

Infertility

1 (0.2)

0

NR

Otitis media

1 (0.2)

0

NR

TOTAL

8 (1.6)

3

 

TOTAL

428 (87.0)

304

 
  1. Abbreviations: PSA, prostatic surface antigen; CAD, coronary artery disease; LVH, left ventricular hypertrophy; LTBI, Latent Tuberculosis Infection; COPD, chronic obstructive pulmonary disease; USPSTF, United States Preventive Services Task Force.
  2. Recommendations for average risk patient are considered Grade A- Strongly recommended; Grade B- Recommended; Grade C- No recommendation; Grade d- Recommend against routine use; Grade I- Insufficient evidence to recommend for or against the intervention; NR- No recommendation available.
  3. *Screen in individuals with hypertension, 2 out of 3 individuals met this criteria.
  4. **Screen for men age ±35 and women age ±45.
  5. ***D for adults with low risk; I for adults with increased risk for coronary heart disease. ^ elevated PSA did not result in diagnosis of prostate cancer